Hepatitis C, table 3, Prospective Study of InterferonTherapy for Compensated Cirrhotic Patients With Chronic Hepatitis Cby Monitoring Serum Hepatitis C RNA

Prospective Study of Interferon Therapy for Compensated Cirrhotic Patients With Chronic Hepatitis C by Monitoring Serum Hepatitis C RNA

table 3. Virological Response in Relation to HCV Subtypes and Treatment Regimens

End-of-Treatment Response (ETR)
HCV Subtype	Randomized		Nonrandomized	Total
HCV Subtype	+16 Weeks	+32 Weeks	Nonrandomized	Total

1b	21/27 (78%)	15/21 (71%)	5/76 (7%)	41/124 (33%)
2a	6/8 (75%)	9/10 (90%)	1/6 (17%)	16/24 (67%)
Others	0/2 (0%)	2/4 (50%)	0/1 (0%)	2/7 (29%)
Missing		1	1	2
Sustained Response (SR)
HCV Subtype	Randomized		Nonrandomized	Total
HCV Subtype	+16 Weeks	+32 Weeks	Nonrandomized	Total
1b	7/27 (26%)	7/21 (33%)	2/76 (3%)	16/124 (13%)
2a	5/8 (63%)	8/10 (80%)	0/6 (0%)	13/24 (54%)
Others	0/2 (0%)	2/4 (50%)	0/1 (0%)	2/7 (29%)
Missing		1	1	2